Rotational thrombelastometry for the bedside monitoring of recombinant hirudin
Authors:
- 16 January 2008
- journal article
- research article
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 52 (3) , 358-362
Abstract
Recombinant hirudin is used as an alternative anticoagulant, particularly in patients with heparin-induced thrombocytopenia type II. However, bedside monitoring for hirudin is not available. The present study aims to evaluate rotational thrombelastometry regarding its suitability to detect the effects of recombinant hirudin on whole blood coagulation. Hirudin was added to whole blood samples from healthy donors (n=5) and thrombelastometry variables resulting from activation of samples with tissue factor, ellagic acid, and ecarin were determined. Hirudin (0.1-10 microg/ml) was added to citrated blood. Thereafter, rotational thrombelastometry was performed by initiating coagulation via recalcification and addition of tissue factor, ellagic acid, and ecarin, respectively, using the commercially available assays. In the absence of hirudin, clotting times (CT) induced by ellagic acid, tissue factor, and ecarin, respectively, were 141.7+/-18.0, 54.0+/-7.6, and 64.5+/-4.1 s. Increasing concentrations of hirudin led to dose-dependent prolongation of the clotting time with the three activators. All assays were capable to detect hirudin concentrations in the range of 0.5-5 microg/ml. At a final hirudin concentration of 1 microg/ml, clotting time increased to 268.0+/-25.1, 84.0+/-9.3, and 107.5+/-9.9 s, respectively, with the above-mentioned activators. The other thrombelastographic variables, including clot formation time, angle alpha, and maximum clot firmness, were not altered by hirudin at concentrations up to 5 microg/ml. Our study demonstrates the suitability of rotational thrombelastometry to detect anticoagulant effects of recombinant hirudin.Keywords
This publication has 21 references indexed in Scilit:
- A functional clotting assay to monitor the hirudin dosageBlood Coagulation & Fibrinolysis, 2007
- A direct thrombin inhibitor studied by dynamic whole blood clot formationThrombosis and Haemostasis, 2006
- The Ecarin Clotting Time, a Universal Method to Quantify Direct Thrombin InhibitorsPathophysiology of Haemostasis and Thrombosis, 2003
- The Predictive Value of Modified Computerized Thromboelastography and Platelet Function Analysis for Postoperative Blood Loss in Routine Cardiac SurgeryAnesthesia & Analgesia, 2003
- Methods for the Monitoring of Direct Thrombin InhibitorsSeminars in Thrombosis and Hemostasis, 2002
- Monitoring of Anticoagulant Effects of Direct Thrombin InhibitorsSeminars in Thrombosis and Hemostasis, 2002
- Clinical Monitoring of Hirudin and Direct Thrombin InhibitorsSeminars in Thrombosis and Hemostasis, 2001
- Thrombelastographic evaluation of coagulation in transurethral prostatectomyBritish Journal of Urology, 1996
- Quantitative Determination of Hirudin in Blood and Body FluidsSeminars in Thrombosis and Hemostasis, 1996
- Blutgerinnungsstudien mit der Thrombelastographie, einem neuen UntersuchungsverfahrenJournal of Molecular Medicine, 1948